Rhythm Pharmaceuticals Statistics
Total Valuation
RYTM has a market cap or net worth of $6.18 billion. The enterprise value is $5.96 billion.
| Market Cap | 6.18B |
| Enterprise Value | 5.96B |
Important Dates
The next estimated earnings date is Tuesday, November 3, 2026, before market open.
| Earnings Date | Nov 3, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
RYTM has 68.85 million shares outstanding. The number of shares has increased by 8.09% in one year.
| Current Share Class | 68.85M |
| Shares Outstanding | 68.85M |
| Shares Change (YoY) | +8.09% |
| Shares Change (QoQ) | +0.91% |
| Owned by Insiders (%) | 0.79% |
| Owned by Institutions (%) | 96.13% |
| Float | 56.04M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 26.12 |
| Forward PS | 15.26 |
| PB Ratio | 60.66 |
| P/TBV Ratio | 63.89 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 25.20 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.45, with a Debt / Equity ratio of 0.51.
| Current Ratio | 3.45 |
| Quick Ratio | 3.00 |
| Debt / Equity | 0.51 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -10.86 |
Financial Efficiency
Return on equity (ROE) is -117.04% and return on invested capital (ROIC) is -43.64%.
| Return on Equity (ROE) | -117.04% |
| Return on Assets (ROA) | -30.96% |
| Return on Invested Capital (ROIC) | -43.64% |
| Return on Capital Employed (ROCE) | -63.96% |
| Weighted Average Cost of Capital (WACC) | 15.26% |
| Revenue Per Employee | $579,512 |
| Profits Per Employee | -$507,783 |
| Employee Count | 414 |
| Asset Turnover | 0.59 |
| Inventory Turnover | 1.07 |
Taxes
In the past 12 months, RYTM has paid $1.07 million in taxes.
| Income Tax | 1.07M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -10.95% in the last 52 weeks. The beta is 2.01, so RYTM's price volatility has been higher than the market average.
| Beta (5Y) | 2.01 |
| 52-Week Price Change | -10.95% |
| 50-Day Moving Average | 103.69 |
| 200-Day Moving Average | 98.23 |
| Relative Strength Index (RSI) | 30.34 |
| Average Volume (20 Days) | 800,804 |
Short Selling Information
The latest short interest is 10.29 million, so 14.94% of the outstanding shares have been sold short.
| Short Interest | 10.29M |
| Short Previous Month | 10.30M |
| Short % of Shares Out | 14.94% |
| Short % of Float | 18.36% |
| Short Ratio (days to cover) | 20.61 |
Income Statement
In the last 12 months, RYTM had revenue of $239.92 million and -$210.22 million in losses. Loss per share was -$3.12.
| Revenue | 239.92M |
| Gross Profit | 213.53M |
| Operating Income | -200.63M |
| Pretax Income | -204.28M |
| Net Income | -210.22M |
| EBITDA | -199.55M |
| EBIT | -200.63M |
| Loss Per Share | -$3.12 |
Balance Sheet
The company has $330.90 million in cash and $109.78 million in debt, with a net cash position of $221.11 million or $3.21 per share.
| Cash & Cash Equivalents | 330.90M |
| Total Debt | 109.78M |
| Net Cash | 221.11M |
| Net Cash Per Share | $3.21 |
| Equity (Book Value) | 217.30M |
| Book Value Per Share | 1.50 |
| Working Capital | 302.98M |
Cash Flow
In the last 12 months, operating cash flow was -$105.35 million and capital expenditures -$953,000, giving a free cash flow of -$106.30 million.
| Operating Cash Flow | -105.35M |
| Capital Expenditures | -953,000 |
| Depreciation & Amortization | 1.08M |
| Net Borrowing | n/a |
| Free Cash Flow | -106.30M |
| FCF Per Share | -$1.54 |
Margins
Gross margin is 89.00%, with operating and profit margins of -83.62% and -85.59%.
| Gross Margin | 89.00% |
| Operating Margin | -83.62% |
| Pretax Margin | -85.14% |
| Profit Margin | -85.59% |
| EBITDA Margin | -83.17% |
| EBIT Margin | -83.62% |
| FCF Margin | n/a |
Dividends & Yields
RYTM does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -8.09% |
| Shareholder Yield | -8.09% |
| Earnings Yield | -3.35% |
| FCF Yield | -1.70% |
Analyst Forecast
The average price target for RYTM is $138.88, which is 54.62% higher than the current price. The consensus rating is "Buy".
| Price Target | $138.88 |
| Price Target Difference | 54.62% |
| Analyst Consensus | Buy |
| Analyst Count | 18 |
| Revenue Growth Forecast (3Y) | 67.77% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
RYTM has an Altman Z-Score of 12.89 and a Piotroski F-Score of 4.
| Altman Z-Score | 12.89 |
| Piotroski F-Score | 4 |